Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Absci

company

About

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Details

Last Funding Type
Series C
Last Funding Money Raised
$12M
Industries
Artificial Intelligence,Biopharma,Biotechnology,Life Science
Founded date
Jan 1, 2011
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:ABSI
Legal Name
Absci Corp.

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$437.85M
Absci has raised a total of $437.85M in funding over 2 rounds. Their latest funding was raised on Jul 21, 2021 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 21, 2021 IPO $200M Detail
Mar 23, 2021 Series Unknown $125M 9 Casdin Capital
Redmile Group
Detail
Feb 22, 2021 Corporate Round 1 Merck Global Health Innovation Fund Detail
Oct 20, 2020 Series E $69.99M 4 Casdin Capital Detail
Jan 14, 2020 Series D $10.40M 6 JSR Life Sciences
KBI Biopharma
Detail

Investments

Number of Investments
Number of Lead Investments
3
0
Absci has made 3 investments. Their most recent investment was on Jan 19, 2022, when Ambient.ai raised $52M.
Date Company Name
Round Money Raised Industry Lead Investor
Jan 19, 2022 Ambient.ai
Series Unknown $52M Artificial Intelligence
Jan 14, 2021 X1
Series A $12M Credit Cards
Nov 6, 2019 Digits
Series A $10.50M Artificial Intelligence

Employee Profiles

Number of Employee Profiles
12
Absci has 12 current employee profiles, including Board member Eli Casdin
Board member
Employee
Employee
Executive
Board member

Acquisition

Absci has acquired 2 organizations. Their most recent acquisition was Denovium on Jan 12, 2021. They acquired Denovium for 0.

Date Company Name
Industry Acquisition Type Price
Jan 12, 2021 Denovium
Artificial Intelligence acquisition Detail
Jun 14, 2021 Totient
Artificial Intelligence acquisition Detail